Correction to: Improvement in Cognitive Function as Measured by NeuroTrax in Patients with Relapsing Multiple Sclerosis
- PDF / 521,268 Bytes
- 1 Pages / 595.276 x 790.866 pts Page_size
- 42 Downloads / 173 Views
CORRECTION
Correction to: Improvement in Cognitive Function as Measured by NeuroTrax in Patients with Relapsing Multiple Sclerosis Treated with Natalizumab: A 2‑Year Retrospective Analysis Mark Gudesblatt1 · Karl Wissemann1 · Myassar Zarif1 · Barbara Bumstead1 · Lori Fafard1 · Jeffrey Wilken2 · Karen Blitz1 · Marijean Buhse1 · Sourav Santra3 · Christophe Hotermans3 · Lily Lee3
© Springer Nature Switzerland AG 2018
Correction to: CNS Drugs https://doi.org/10.1007/s40263-018-0553-1
An Online First version of this article was made available online at http://link.springer.com/journal/40263/onlineFirst/ page/1 on 24 August 2018. An error was subsequently identified in the article, and the following correction should be noted: Author listing: The name of the second author, which previously read: ‘Karl Wisseman’ Should read: ‘Karl Wissemann’. The original article has been corrected.
The original article can be found online at https://doi.org/10.1007/ s40263-018-0553-1. * Lily Lee [email protected] 1
South Shore Neurologic Associates, Patchogue, NY, USA
2
Washington Neuropsychology Research Group LLC, Fairfax, VA, USA
3
Biogen, 225 Binney Street, Cambridge, MA 02142, USA
Vol.:(0123456789)
Data Loading...
